Literature DB >> 7932511

Hormone replacement therapy and blood pressure in hypertensive women.

G Y Lip1, M Beevers, D Churchill, D G Beevers.   

Abstract

There remains anxiety about the use of hormone replacement therapy (HRT) in postmenopausal women with hypertension. We therefore conducted a prospective open study of sequential changes in BP in 75 women referred to our hypertension clinic who required HRT for amelioration of menopausal symptoms. There were no significant differences in mean systolic or diastolic BPs following the introduction of HRT over a median follow-up time of 14 months (interquartile range 8-32 months), despite a significant rise in mean body weight for individual patients which was statistically significant at three, nine and 12 months following the introduction of HRT. No differences in BP were seen in relation to type of menopause, ethnic origin, history of previous pregnancy-induced hypertension or the type of HRT preparation used. Our data suggest that HRT is safe in hypertensive women who should not therefore be denied this therapy if they have menopausal symptoms, although careful supervision is necessary.

Entities:  

Mesh:

Year:  1994        PMID: 7932511

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  The menopause and its treatment in perspective.

Authors:  F Al-Azzawi
Journal:  Postgrad Med J       Date:  2001-05       Impact factor: 2.401

Review 2.  Postmenopausal hypertension.

Authors:  L M Harrison-Bernard; L Raij
Journal:  Curr Hypertens Rep       Date:  2000-04       Impact factor: 5.369

3.  Effects of postmenopausal hormone replacement therapy on insulin resistance.

Authors:  Kenan Saglam; Zülfikar Polat; M Ilker Yilmaz; Mustafa Gulec; Seda B Akinci
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

Review 4.  Sex-specific differences in hypertension and associated cardiovascular disease.

Authors:  Katrina M Mirabito Colafella; Kate M Denton
Journal:  Nat Rev Nephrol       Date:  2018-01-30       Impact factor: 28.314

5.  Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials.

Authors:  Yael Swica; Michelle P Warren; JoAnn E Manson; Aaron K Aragaki; Shari S Bassuk; Daichi Shimbo; Andrew Kaunitz; Jacques Rossouw; Marcia L Stefanick; Catherine R Womack
Journal:  Menopause       Date:  2018-07       Impact factor: 2.953

Review 6.  Blood pressure, arterial function, structure, and aging: the role of hormonal replacement therapy in postmenopausal women.

Authors:  Angelo Scuteri; Luigi Ferrucci
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.